Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Aura Biosciences, Inc.NASDAQ: AURA
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$514.1M, compared with -$401.71M a year earlier.
Context
- Retained earnings amounted to 373.4% of total assets at the end of Q1 FY2026, up 114.9 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -28.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (480.42M) USD
- Year-over-year change
- -28.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (480.42M) | -28.4% |
| FY2024 | 2024-12-31 | (374.23M) | -30.3% |
| FY2023 | 2023-12-31 | (287.31M) | -36.2% |
| FY2022 | 2022-12-31 | (210.9M) | -38.6% |
| FY2021 | 2021-12-31 | (152.14M) | — |
Retained Earnings vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -28.0% is the 5th highest of 10, against a peer median of -29.3%.
- Retained earnings amounts to 373.4% of total assets for AURA, versus a peer median of 347.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$174.89M USD | — | — | 30.3% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | -$375.44M USD | -44.6% | — | 295.1% |
| Mar 2026 | -CHF 412.13M CHF | -29.3% | — | 169.4% | |
| Mar 2026 | -$427.24M USD | -20.2% | — | 750.8% | |
| Mar 2026 | -$514.1M USD | -28.0% | — | 373.4% | |
| Mar 2026 | -$578.4M USD | -17.1% | — | 400.3% | |
| Mar 2026 | -$633.22M USD | -10.7% | — | 2892.4% | |
| Sep 2026 | -$940.91M USD | -42.9% | — | 186.1% | |
| Mar 2026 | -$960.58M USD | -29.5% | — | 147.2% | |
| Mar 2026 | -$1.19B USD | -29.6% | — | 412.8% | |
| Mar 2026 | -$1.28B USD | -5.8% | — | 588.0% | |
| Peer median (excluding AURA) | — | -29.3% | — | 347.7% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 149.06M | 121.58M | 41.06M | 31.69M | 59.52M |
| Short-term Investments | 0 | 67.23M | 185.09M | 119.4M | 84.73M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 89K | 5.72M | 3.83M | 1.83M | 1.18M |
| Total Current Assets | 153.7M | 196.7M | 231.79M | 160.62M | 149.74M |
| Property, Plant & Equipment (Net) | 6.2M | 26.04M | 22M | 20.59M | 18.45M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 768K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 125K | 423K | 1.28M | 1.29M | 1.24M |
| Total Non-current Assets | 6.33M | 27.23M | 23.28M | 21.88M | 19.69M |
| Total Assets | 160.03M | 223.94M | 255.08M | 182.5M | 169.43M |
| Account Payables | 2.4M | 2.92M | 1.79M | 2.3M | 1.55M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.65M | 3.03M | 935K | 618K | 6.25M |
| Total Current Liabilities | 7.36M | 10.46M | 12.36M | 14.91M | 18.38M |
| Long-term Debt | 0 | 0 | 0 | 0 | 14.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 360K | 17.9M | 16.87M | 15.62M | 14.13M |
| Total Liabilities | 7.72M | 28.35M | 29.23M | 30.53M | 32.52M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (152.14M) | (210.9M) | (287.31M) | (374.23M) | (480.42M) |
| Accumulated OCI | 0 | (72K) | 539K | 263K | (102K) |
| Other Stockholders Equity | 0 | 0 | 1K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 152.32M | 195.58M | 225.85M | 151.97M | 136.91M |
| Total Debt | 975K | 20.86M | 19.56M | 18.77M | 17.38M |
| Net Debt | (148.09M) | (100.72M) | (21.51M) | (12.92M) | (42.14M) |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.